Aclaris Therapeutics
ACRS
95 hedge funds and large institutions have $227M invested in Aclaris Therapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 19 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
3.67% less ownership
Funds ownership: 95.46% → 91.79% (-3.7%)
4% less funds holding
Funds holding: 99 → 95 (-4)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
21% less capital invested
Capital invested by funds: $289M → $227M (-$61.5M)
76% less call options, than puts
Call options by funds: $68K | Put options by funds: $288K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.4M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.62M |
| 3 |
Man Group
London,
United Kingdom
|
+$3.44M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.46M |
| 5 |
Renaissance Technologies
New York
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.6M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$5.53M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.54M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.2M |
| 5 |
BlackRock
New York
|
-$3.23M |
ACRS Hedge Fund Activity: Q1 2019 in Review
95 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2019, worth a combined $227M — down 21% from $289M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ACRS and 15 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 36 added.
The largest buyer was Vanguard Group, adding an estimated $7.4M. The largest seller was Fidelity Investments, cutting an estimated $6.6M.
- 95 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2019, down from 99 in Q4 2018.
- Funds reported $227M of Aclaris Therapeutics stock for Q1 2019, down 21% quarter-over-quarter.
- 15 funds opened new Aclaris Therapeutics positions in Q1 2019 and 19 closed out, a net change of -4 holders.
- The largest Aclaris Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $7.4M added.
- The largest Aclaris Therapeutics seller in Q1 2019 was Fidelity Investments, an estimated $6.6M sold.
Based on aggregated 13F filings for Q1 2019.